Metis TechBio Co., Ltd. Class H 7666

This is a news report by Hong Kong Ta Kung Wen Wei Media Group Limited:

METiS TechBio (7666.HK), a leading AI-driven drug delivery innovation company, today announced it has entered into an exclusive global licensing agreement with Boulevard Bio ("Boulevard"), a U.S. biotechnology company backed by Deerfield Management, granting Boulevard worldwide development, manufacturing, and commercialization rights for MTS-128, a proprietary trispecific T-cell engager (TCE) program developed by METiS TechBio.

Short term share move puts Metis TechBio in focus Metis TechBio (SEHK:7666) has come onto investor radar after the stock fell about 10% in the latest session and is down around 24% over the past week. The company focuses on AI empowered nanomaterials for drug delivery. It reported revenue of HK$105.0 million and a net loss of CN¥391.836 million across its operations in Mainland China and the United States. See our latest analysis for Metis TechBio. At a latest share price of HK$18.0, Metis...

METiS TechBio (7666.HK), a global leader in AI-powered drug delivery innovation, today announced that new preclinical data from its heart-targeted LNP program has been selected for a Late-Breaking oral presentation at the 2026 Controlled Release Society (CRS) Annual Meeting. Dr. Andong Liu, Vice President and Head of Technology Platform at METiS TechBio, will deliver a Late-Breaking oral presentation at the 2026 CRS Annual Meeting in Lisbon, Portugal, this July. The presentation is titled "Syste

METiS TechBio (7666.HK), a tech-bio company focused on AI-powered nanodelivery innovation, today successfully listed on the Hong Kong Stock Exchange (HKEX), becoming the world's first publicly listed AI-powered drug delivery company and the first AI-powered large-molecule biopharmaceutical company listed on the Hong Kong market. With the goal of becoming the "SpaceX of pharmaceuticals," METiS TechBio has, within six years of its founding, become the fastest unicorn in China's AI pharmaceutical s